The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals
Authors:
- Sang Seop LeeSLSang Seop Lee
- Hye-Eun JeongHJHye-Eun Jeong
- Ji-Hong ShonJSJi-Hong Shon
- Ji-Young RyuJRJi-Young Ryu
- Yu Eun SunwooYSYu Eun Sunwoo
- Kwang-Hyeon LiuKLKwang-Hyeon Liu
- Wonku KangWKWonku Kang
- Young-Ju ParkYPYoung-Ju Park
- Chi-Mann ShinCSChi-Mann Shin
- Jae-Gook ShinJSJae-Gook Shin
- 1 November 2007
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 35 (11) , 2095-2101
Abstract
The objective of this study was to identify CYP3A4 variants in Koreans and to characterize their functional consequences in vitro and in vivo. Four single nucleotide polymorphisms were identified in 50 Koreans by direct DNA sequencing. In an additional genotyping using 248 subjects, CYP3A4*18 was confirmed as the most frequent coding variant in Koreans at 1.7%, and its frequency was similar to that of Asians, suggesting that CYP3A4*18 would be the highest coding variant in Asians. The recombinant CYP3A4.18 protein prepared in baculovirus expression system showed 67.4% lower Vmax and 1.8-fold higher Km for midazolam 1′-hydroxylation compared with the wild type. The mean values of Cmax and area under the concentration curve (AUC) in the CYP3A4*1/*18 and CYP3A5*1/*3 subjects (n = 8) were 63% and 32% higher than in CYP3A4*1/*1 and CYP3A5*1/*3 carriers (n = 8), respectively. Although the in vitro assay exhibited a significant reduction of the enzyme activity for midazolam, the in vivo differences associated with the CYP3A4*1/*18 tend to be low (P < 0.07 in Cmax and P < 0.09 in AUC). In summary, the heterozygous CYP3A4*1/*18 does not appear to cause a significant change of midazolam disposition in vivo; however, the clinical relevance of CYP3A4*18/*18 remains to be evaluated.Keywords
This publication has 52 references indexed in Scilit:
- Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivoClinical Pharmacology & Therapeutics, 2005
- Recombinant CYP3A4*17 Is Defective in Metabolizing the Hypertensive Drug Nifedipine, and the CYP3A4*17 Allele May Occur on the Same Chromosome as CYP3A5*3, Representing a New Putative Defective CYP3A HaplotypeThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Identification of a Novel Polymorphic Enhancer of the Human CYP3A4 GeneMolecular Pharmacology, 2004
- Haplotypes ofCYP3A4 and their close linkage withCYP3A5 haplotypes in a Japanese populationHuman Mutation, 2003
- Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and womenPharmacogenetics, 2003
- Does the CYP3A5*3 polymorphism affect in vivo drug elimination?Pharmacogenetics, 2003
- Increased transcriptional activity of the CYP3A4*1B promoter variantEnvironmental and Molecular Mutagenesis, 2003
- Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory RegionBiochemical and Biophysical Research Communications, 1999
- Fetus-specific expression of a form of cytochrome P-450 in human liversBiochemistry, 1990
- Site-directed mutagenesis by overlap extension using the polymerase chain reactionGene, 1989